Bristol Myers Squibb reports double-digit growth in Q3

US-based Bristol Myers Squibb's revenue in the third quarter of the year has gone up 10 percent to USD 11.6bn and surpassed analyst estimates, reports Bloomberg News.

Photo: Brian Snyder/Reuters/Ritzau Scanpix

The US-based pharmaceutical giant Bristol Myers Squibb has seen progress in the year's third quarter, increasing product revenue for several of its drugs, it reported in a press release on Wednesday.

The sales of cancer drugs Revlimid and Opdivo increased by a respective 11 percent and 7 percent, reaching USD 3.3bn and USD 1.9bn in the months July, August and September.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs